HRD Evaluation and Scoring Using OncoScan CNV Assay - A Whole-Genome Microarray Research Solution

Attend a panel presentation webinar featuring Yann Christinat, PhD and Stephan Bartels, PhD discussing homologous recombination deficiency (HRD) evaluation and scoring using the OncoScan CNV Assay. Explore how this whole-genome microarray research solution can be used as an alternative to NGS for detecting genome-wide HRD biomarkers in high-grade ovarian and breast cancers. Learn about the correlation between HRD scores and PARP inhibitor response, and discover how OncoScan detects Long Scale State transitions (LST), Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Whole Genome Doubling (WGD) events to create HRD Scores. Participate in a live Q&A session following the presentation to further explore this innovative approach to cancer research and potential therapeutic applications.